Name: 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
Start: 2019-09-19
End: 2019-09-20
Location: Hilton Garden Inn Philadelphia Center City

45+

Speakers

250+

Attendees

7+

Sessions

EVENT OVERVIEW

The next step towards changing treatment paradigms in immuno-oncology

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.

A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

Updates in development of monoclonal Abs and bispecific Abs
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments

Targeted Antibodies and Combinations
Pre-clinical & Translational Immuno-Oncology Developments
New Antibody Formats
New Immune Checkpoints for Immunotherapy

Find out new case studies of antibody projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you

CONFERENCE AGENDA

Registration

08:15 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening remarks from the Chairman Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	09:00 - 09:05
Keynote: Mutations in the IL-7 receptor driving acute lymphoblastic leukemia Scott Durum, Head, Cytokines and Immunity, NIH	09:05 - 09:40
Natural single domain antibodies as potential alternatives to monoclonal antibodies in the next generation immunotherapy Rajesh Singh, Laboratory Director, Abzyme Therapeutics	09:40 - 10:15
Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immunomodulatory Targets Tabb Sullivan, Senior Scientist, Project Leader, Integral Molecular	10:15 - 10:50
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:50 - 11:40
Targeted Antibodies and Combinations
Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics Rakesh Dixit, CEO, Bionavigen	11:40 - 12:15
Human Cell Culture: The Role of In Vitro models in Cancer Immunotherapy Development Melissa Olekson, Scientific Support Specialist, PromoCell	12:15 - 12:50
Therapeutic targeting of the tumor microenvironment	12:25 - 12:55
ex vivo PBMC Activation of Antitumor Activity Offers Accelerated Path to Clinical Application Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	12:50 - 13:25
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:25 - 14:25
New Antibody Formats and Developments in CAR-T Cell Therapy
Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta Vicki Plaks, Translational Lead, Principal Scientist, Translational Sciences, Kite Pharma	14:25 - 15:00
Improving the Safety and Efficacy Profile of CAR-T: GM-CSF Neutralization with Lenzilumab	15:00 - 15:35
Next-generation gene editing technology for allogeneic T cell therapeutics Megan van Overbeek, Associate Director of Functional Genomics, Caribou Biosciences	15:35 - 16:10
Evening Refreshments and Poster Presentations \| One-to-One Networking Meetings	16:10 - 16:45
“RubrYc Therapeutics: Overcoming Immunodominance to Discover Next Gen Biotherapeutics” Matt Greving, Co-Founder & VP, Technology, RubrYc Therapeutics Inc.	16:45 - 17:20
Closing remarks from the Chairman	17:20 - 17:25
Cocktail Reception \| End of Day 1	17:30 - 17:35

Opening remarks from the Chairman Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics	09:00 - 09:05
Keynote: Defining T Cell States Associated with Response to Combination Immunotherapy Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics	09:05 - 09:40
Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors William Williams, President, CEO, Briacell Therapeutics Corporation	09:40 - 10:15
Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models Qingcong Lin, Senior Vice President, CEO, Biocytogen Boston Corporation	10:15 - 11:40
Pre-clinical & Translational Immuno-Oncology Developments
Reversing trastuzumab resistance in HER2+ breast cancer RJ Tesi, CEO, CMO, INmune Bio Inc.	11:40 - 12:15
Humanized Mouse Models for Immuno-Oncology Research Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices	12:15 - 12:50
Preserving CTLA4 function to make a better and safer anti-CTLA4 antibody Pan Zheng, Professor, University of Maryland School of Medicine	12:50 - 14:25
New Immune Checkpoints for Immunotherapy
Clinical development of GITR based immunotherapies Girish Naik, Medical Director, Leap Therapeutics	14:25 - 15:00
B cells in the human tumor microenvironment Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh	15:35 - 16:05
Evening Refreshments and Poster Presentations \| One-to-One Networking Meetings	16:05 - 16:55
Break out Session: Future of Biologics in Immune Checkpoint therapy	16:55 - 17:20
Closing remarks from the Chairman	17:20 - 17:25

Registration

08:15 - 08:55

Opening remarks from the Chairman Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics	09:00 - 09:05
New Antibodies Development and Tumor Microenvironment
Keynote: Anti PD-! Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	09:05 - 09:40
Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics	09:40 - 10:15
Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using A Novel Therapeutic Modality EAGLE Li Peng, Senior Vice President, Palleon Pharma	10:15 - 10:50
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:50 - 11:40
Novel T cell engaging bispecific antibodies for cancer immunotherapy Thomas Tan, Vice President, Immunology, Elstar Therapeutics	11:40 - 12:15
B7-H3, an attractive target of antibody-based immunotherapy Soldano Ferrone, Professor of Surgery, Massachusetts General Hospital, Harvard Medical School	12:15 - 12:50
Comparing immunological marker signatures across various cancer types Natalie Russi, Scientific Project Manager, Nebion	12:50 - 13:25
End of Conference	13:00 - 13:05
Closing remarks from the Chairman	13:25 - 13:30

Opening remarks from the Chairman Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	09:00 - 09:05
Personalized Immunotherapy and T-Cell Therapies
Keynote: Tumor Inflammatory Signature Carl Morrison, President, Chief Medical Officer, OmniSeq	09:05 - 09:40
Development of effective immunotherapeutic combinations with antitumor activities Joost Oppenheim, Head, Cellular Immunology, NIH	09:40 - 10:15
Update on ICI data in early and metastatic breast cancer Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	10:15 - 10:50
End of Conference	13:00 - 13:05
Closing remarks from the Chairman	13:25 - 13:30